Sanskritech Introduces CDSCO-Approved Swandook Health Monitoring Bag

India Pharma Outlook Team | Wednesday, 06 March 2024

 healthcare technology, healthcare culture, India Pharma Outlook

Photo:Representative Image

Sanskritech, a health-tech company in India backed by Mylab, has launched Swandook, an ultra-smart anytime health monitoring bag. Approved by CDSCO, Swandook represents a pioneering leap in healthcare technology, said the company, stating that it is the world's first ultra-portable bag.

It offers users convenience and accessibility in monitoring their health. Swandook's versatility extends across multiple sectors, including military/defense, public health coverage extension, CSR-driven social health initiatives, health check-up camps, corporate wellness programs, and rural health initiatives.

It is a comprehensive point-of-care diagnostics platform capable of conducting over 100 real-time invasive and non-invasive health tests. This wide array of tests provides users with a complete assessment of their health status, empowering them to take proactive measures towards their well-being.

The tests include routine blood tests, infectious tests like TB, dengue, malaria, HCV, etc., and non-communicable diseases like sickle cell anemia, thalassemia, cancer biomarkers, etc.

Pritam Kumawat, CEO and co-founder of Sanskritech said, “Swandook heralds a significant shift in healthcare technology, transforming how individuals access and monitor their health. With its advanced features and unparalleled convenience, Swandook aims to make healthcare services more accessible and efficient for people across India and beyond. By providing portable, fast, and comprehensive services, we aim to promote a healthcare culture and empower people to take control of their lives."

Using new technology, Swandook provides results-based diagnostics. The platform also includes built-in telemedicine capabilities with a webcam, dermoscopy, otoscope, and stethoscope, allowing users to access remote chats with healthcare professionals.

© 2024 India Pharma Outlook. All Rights Reserved.